Atea Pharmaceuticals, Inc. financial data

Symbol
AVIR on Nasdaq
Industry
Pharmaceutical Preparations
Location
225 Franklin Street, Suite 2100, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.7K % -55.5%
Debt-to-equity 7.76 % +97.3%
Return On Equity -34.9 % -62.4%
Return On Assets -32.4 % -56.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 84.5M shares +1.23%
Common Stock, Shares, Outstanding 84.5M shares +1.23%
Entity Public Float 284M USD -47.2%
Common Stock, Value, Issued 84K USD +1.21%
Weighted Average Number of Shares Outstanding, Basic 84.4M shares +1.23%
Weighted Average Number of Shares Outstanding, Diluted 84.4M shares +1.23%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 153M USD +43.8%
General and Administrative Expense 47M USD -7.35%
Operating Income (Loss) -200M USD -27.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -173M USD -32.6%
Income Tax Expense (Benefit) 1.05M USD +32.4%
Net Income (Loss) Attributable to Parent -174M USD -32.6%
Earnings Per Share, Basic -2.06 USD/shares -31.2%
Earnings Per Share, Diluted -2.06 USD/shares -31.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 98.5M USD -28.6%
Cash, Cash Equivalents, and Short-term Investments 483M USD -18.9%
Accounts Receivable, after Allowance for Credit Loss, Current 4.51M USD
Assets, Current 487M USD -19.3%
Property, Plant and Equipment, Net 977K USD -29.9%
Operating Lease, Right-of-Use Asset 1.39M USD -29.4%
Other Assets, Noncurrent 1.68M USD +20.6%
Assets 491M USD -19.3%
Accounts Payable, Current 5.79M USD +1365%
Employee-related Liabilities, Current 4.54M USD -9.34%
Liabilities, Current 25.2M USD +33.3%
Accrued Income Taxes, Noncurrent 6.2M USD +10.4%
Operating Lease, Liability, Noncurrent 1.05M USD -43.1%
Liabilities 32.4M USD +23.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 641K USD
Retained Earnings (Accumulated Deficit) -331M USD -111%
Stockholders' Equity Attributable to Parent 459M USD -21.2%
Liabilities and Equity 491M USD -19.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.9M USD -33.6%
Net Cash Provided by (Used in) Financing Activities 150K USD -9.09%
Net Cash Provided by (Used in) Investing Activities -44K USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 84.5M shares +1.23%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 17.1M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 98.5M USD -28.6%
Deferred Tax Assets, Valuation Allowance 74.2M USD +80.2%
Deferred Tax Assets, Gross 74.2M USD +80.2%
Operating Lease, Liability 1.84M USD -29%
Payments to Acquire Property, Plant, and Equipment 44K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -173M USD -32.5%
Lessee, Operating Lease, Liability, to be Paid 1.9M USD -30.1%
Property, Plant and Equipment, Gross 1.98M USD 0%
Operating Lease, Liability, Current 790K USD +5.33%
Lessee, Operating Lease, Liability, to be Paid, Year Two 855K USD +2.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 838K USD +2.07%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 63K USD -51.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 855K USD +2.03%
Deferred Tax Assets, Operating Loss Carryforwards 9.39M USD +67.9%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -3.83M USD
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 5.76M USD +9.57%
Lessee, Operating Lease, Liability, to be Paid, Year Four 855K USD +2.03%
Additional Paid in Capital 788M USD +6.76%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 49.6M USD +1.45%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%